

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- How George Tidmarsh crossed the FDA-industry Rubicon
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
















